更年期女性潮热与睡眠障碍的随机试验研究
本研究为随机双盲安慰剂对照试验的预设次要终点分析,纳入141例围绝经期或绝经后频繁潮热女性,随机接受经皮硝酸甘油(NTG)0.2-0.6 mg/小时或安慰剂治疗12周。结果显示两组睡眠质量与睡眠中断改善程度无显著组间差异(P≥.05),但夜间潮热频率改善越大者睡眠质量与睡眠中断改善越明显。
要点
- 基线时62.6%参与者报告每晚至少因潮热觉醒2次,潮热是夜间觉醒最常见原因。
- 经皮NTG组与安慰剂组在5周和12周睡眠结局改善上无显著组间差异(P≥.05)。
- 两组合并样本中,夜间潮热频率改善越大与PSQI睡眠质量评分改善(β=-0.30,P=.01)及WASO改善(β=-1.88,P=.02)相关。
核心结论
- 在因潮热接受连续NTG治疗的绝经期女性随机试验中,潮热是夜间觉醒最常报告的原因。
- 与安慰剂相比,连续NTG治疗未使睡眠质量从基线至5周和12周的改善更优。
- 基于逐夜症状日记和问卷,两组中夜间潮热频率改善越大与睡眠质量和睡眠中断改善越大相关。
研究设计与样本
- 随机双盲安慰剂对照试验的睡眠数据分析,评估连续经皮NTG治疗对围绝经期和绝经后频繁潮热女性睡眠质量的影响(预设次要试验终点)。
- 参与者随机接受不间断经皮NTG(0.2-0.6 mg/小时)或安慰剂治疗12周。
- 共141例参与者(NTG组70例,安慰剂组71例),平均年龄54.6(±3.9)岁。
主要发现
- 基线平均潮热频率为每日10.8(±3.5)次,其中导致觉醒的夜间潮热为2.6(±1.7)次。
- 基线时62.6%参与者报告每晚因潮热觉醒至少2次。
- 5周和12周期间,导致觉醒的夜间潮热平均频率在NTG组降低0.9次/晚,安慰剂组降低1.0次/晚。
- 平均每晚WASO在NTG组降低10.1分钟,安慰剂组降低7.3分钟;平均PSQI评分在NTG组改善1.3分,安慰剂组改善1.2分。
- 从基线至5周和12周,睡眠结局变化无显著组间差异,包括预设次要终点PSQI睡眠质量评分(所有P≥.05)。
关键数值与推荐
- PSQI评分范围0(最佳)至21(最差)。
- 睡眠中断采用经验证的睡眠日记评估,以入睡后觉醒时间(WASO)表示。
- 夜间潮热导致觉醒采用7天症状日记在基线、5周和12周评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hot flashes, common during menopause, affect up to 80% of the Western menopausal women and are reported to contribute to sleep disturbances in midlife. Few prospective data are available to confirm the specific role of hot flashes in disrupting sleep in midlife women, however, or confirm whether changes in hot flashes in response to clinical therapies result in improvement in sleep. OBJECTIVE: To examine the effects of continuous nitroglycerin therapy on sleep quality in perimenopausal and postmenopausal women with frequent hot flashes (pre-specified secondary trial endpoint) and to examine prospective associations between hot flashes and sleep disruption in this population. STUDY DESIGN: Sleep data were analyzed from a randomized, double-blinded, placebo-controlled trial of continuous transdermal nitroglycerin (NTG) therapy to suppress nitric oxide-mediated vasodilation in perimenopausal or postmenopausal women with hot flashes. Participants were randomized to uninterrupted use of transdermal NTG (0.2-0.6 mg/hour) or placebo for 12 weeks. Nocturnal hot flashes awakening participants from sleep were evaluated using 7-day symptom diaries at baseline, 5 weeks, and 12 weeks. Sleep disruption (wakefulness after sleep onset, WASO) was assessed using validated sleep diaries, and global sleep quality was assessed by the validated Pittsburgh Sleep Quality Index (PSQI: range 0 [best] 21 [worst]) questionnaire. Mixed linear models examined changes in sleep quality and disruption, as well as the strength of associations between nocturnal hot flash frequency and sleep outcomes, over 5 and 12 weeks, adjusting for baseline values, age, race, and ethnicity. RESULTS: Among the 141 participants (70 to NTG and 71 to placebo, mean age 54.6 [±3.9] years), the mean baseline hot flash frequency was 10.8 (±3.5) per day, including 2.6 (±1.7) nocturnal hot flashes awakening participants. At baseline, hot flashes were the most commonly reported reason for nocturnal awakening, with 62.6% of participants reporting waking due to hot flashes at least twice nightly. Over 5 and 12 weeks, mean frequency of nocturnal hot flashes causing awakenings decreased in both groups (NTG: -0.9 episodes/night, placebo: -1.0 episodes/night). Sleep disruption as measured by average nightly WASO also decreased (NTG: -10.1 minutes, placebo: -7.3 minutes), and mean PSQI score improved (NTG: -1.3 points, placebo: -1.2 points). No significant between-group differences in change in sleep outcomes were detected from baseline to 5 and 12 weeks, including PSQI sleep quality score as a prespecified secondary trial endpoint (P≥.05 for all). Greater improvement in nocturnal hot flash frequency over 5 and 12 weeks was associated with greater improvement in PSQI sleep quality score (β= -0.30, P=.01) and sleep disruption reflected by WASO (β= -1.88, P=.02) in the combined sample. CONCLUSION: Among menopausal women in a randomized trial of continuous NTG therapy for hot flashes, hot flashes were the most frequently reported cause of nocturnal awakenings. Compared to placebo, continuous NTG therapy did not result in greater improvements in sleep quality from baseline to 5 and 12 weeks. Based on night-by-night symptom diaries and questionnaires, however, greater improvement in nocturnal hot flash frequency in both groups was associated with greater improvement in sleep quality and disruption.
引用
- Pei M, Gibson CJ, Schembri M, et al. Hot flashes and sleep disruption in a randomized trial in menopausal women. Am J Obstet Gynecol. 2024. PMID: 39038729. doi:10.1016/j.ajog.2024.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。